ATE293994T1 - Multivalente rekombinante antikörper zur behandlung von hrv infektionen - Google Patents

Multivalente rekombinante antikörper zur behandlung von hrv infektionen

Info

Publication number
ATE293994T1
ATE293994T1 AT98960577T AT98960577T ATE293994T1 AT E293994 T1 ATE293994 T1 AT E293994T1 AT 98960577 T AT98960577 T AT 98960577T AT 98960577 T AT98960577 T AT 98960577T AT E293994 T1 ATE293994 T1 AT E293994T1
Authority
AT
Austria
Prior art keywords
multivalent
recombinant antibodies
treatment
antibodies
multivalent recombinant
Prior art date
Application number
AT98960577T
Other languages
English (en)
Inventor
Fang Fang
Original Assignee
Fang Fang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fang Fang filed Critical Fang Fang
Application granted granted Critical
Publication of ATE293994T1 publication Critical patent/ATE293994T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT98960577T 1997-12-01 1998-11-30 Multivalente rekombinante antikörper zur behandlung von hrv infektionen ATE293994T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6711997P 1997-12-01 1997-12-01
US8304698P 1998-04-24 1998-04-24
US9063298P 1998-06-25 1998-06-25
PCT/US1998/025422 WO1999027964A1 (en) 1997-12-01 1998-11-30 Multivalent recombinant antibodies for treating hrv infections

Publications (1)

Publication Number Publication Date
ATE293994T1 true ATE293994T1 (de) 2005-05-15

Family

ID=27371094

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98960577T ATE293994T1 (de) 1997-12-01 1998-11-30 Multivalente rekombinante antikörper zur behandlung von hrv infektionen

Country Status (9)

Country Link
US (1) US20080299121A1 (de)
EP (1) EP1039931B1 (de)
AT (1) ATE293994T1 (de)
AU (1) AU756139B2 (de)
CA (1) CA2313028A1 (de)
DE (1) DE69829995T2 (de)
DK (1) DK1039931T3 (de)
ES (1) ES2245052T3 (de)
WO (1) WO1999027964A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
JP2005522192A (ja) 2001-07-19 2005-07-28 パーラン セラピューティクス， インコーポレイテッド マルチマータンパク質およびマルチマータンパク質を作製および使用する方法
CA2468583C (en) * 2001-11-30 2012-05-01 C. Roger Mackenzie Self-assembling multimeric binding complexes derived from ab5 toxin family members
US8475789B2 (en) * 2008-01-22 2013-07-02 Multimerics Aps Products and methods to prevent infections
CN101830986A (zh) * 2009-03-13 2010-09-15 北京表源生物技术有限公司 一种融合蛋白多聚体
EP2560677A4 (de) * 2010-04-23 2013-09-11 Probiotec Ltd Kältebearbeitung
CN111295392A (zh) 2017-11-01 2020-06-16 豪夫迈·罗氏有限公司 Compbody–多价靶结合物

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US468420A (en) * 1892-02-09 Nut-lock
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CH668554A5 (de) * 1984-04-09 1989-01-13 Sandoz Ag Liposomen welche polypeptide mit interleukin-2-aktivitaet enthalten sowie verfahren zu ihrer herstellung.
US5077195A (en) * 1985-03-01 1991-12-31 Board Of Reagents, The University Of Texas System Polypeptides complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known and methods of design therefor
ATE68968T1 (de) * 1985-11-22 1991-11-15 Takeda Chemical Industries Ltd Liposomzusammensetzung.
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP2666345B2 (ja) * 1987-04-16 1997-10-22 武田薬品工業株式会社 リポソーム製剤およびその製造法
US5565550A (en) * 1987-05-04 1996-10-15 Dana Farber Cancer Institute Antibodies to ICAM-2, and fragments thereof
US5284931A (en) * 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US5273876A (en) * 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2045129A1 (en) * 1989-02-01 1990-08-02 Alfred I. Geller Herpes simplex virus type i expression vector
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5081584A (en) * 1989-03-13 1992-01-14 United States Of America Computer-assisted design of anti-peptides based on the amino acid sequence of a target peptide
JP2550412B2 (ja) * 1989-05-15 1996-11-06 ローム株式会社 電界効果トランジスタの製造方法
US5324510A (en) * 1989-09-01 1994-06-28 Boehringer Ingelheim Pharmaceuticals, Inc. Use of antibodies to intercellular adhesion molecule-1 (ICAM-1) in the treatment of asthma
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
EP0459577A3 (en) * 1990-06-01 1992-08-05 Merck & Co. Inc. Microbially expressed portions of a monoclonal antibody block rhinovirus attachment to cell receptors
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5582996A (en) * 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
US5223396A (en) * 1991-05-03 1993-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. Method for detecting organ transplant rejection
EP0590058B1 (de) * 1991-06-14 2003-11-26 Genentech, Inc. Humanisierter Heregulin Antikörper
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US6027725A (en) * 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
CA2128511C (en) * 1992-01-23 2006-11-07 Andreas Pluckthun Monomeric and dimeric antibody-fragment fusion proteins
US6129914A (en) * 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
AU3972893A (en) * 1992-04-03 1993-11-08 Baylor College Of Medicine Gene therapy using the intestine
US6329507B1 (en) * 1992-08-21 2001-12-11 The Dow Chemical Company Dimer and multimer forms of single chain polypeptides
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994012520A1 (en) * 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
AU6014094A (en) * 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
ATE199392T1 (de) * 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6307026B1 (en) * 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
US5491074A (en) * 1993-04-01 1996-02-13 Affymax Technologies Nv Association peptides
AU7353494A (en) * 1993-11-12 1995-05-29 Case Western Reserve University Episomal expression vector for human gene therapy
US5928944A (en) * 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US5731172A (en) * 1994-03-09 1998-03-24 Sumitomo Pharmaceuticals Company, Ltd. Recombinant adenovirus and process for producing the same
GB9409768D0 (en) * 1994-05-16 1994-07-06 Medical Res Council Trimerising polypeptides
US5604090A (en) * 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
US5763733A (en) * 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5693508A (en) * 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
US5721340A (en) * 1994-11-28 1998-02-24 The Wistar Institute Of Anatomy & Biology p53 proteins with altered tetramerization domains
US5573925A (en) * 1994-11-28 1996-11-12 The Wistar Institute Of Anatomy And Biology P53 proteins with altered tetramerization domains
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP3770333B2 (ja) * 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えｄｎａウイルスおよびその製造方法
US6110456A (en) * 1995-06-07 2000-08-29 Yale University Oral delivery or adeno-associated viral vectors
US5942433A (en) * 1995-07-31 1999-08-24 The United States Of America As Represented By The Department Of Health And Human Services Extension of a protein-protein interaction surface to inactivate the function of a cellular protein
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
JP2000504934A (ja) * 1995-12-22 2000-04-25 バクスター バイオテク テクノロジー エス．アー．アール．エル． 結合ドメインを含むグロビン
US5861397A (en) * 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
US20020165153A1 (en) * 1998-04-06 2002-11-07 Peter Angel Transcription factors and their use
US5965712A (en) * 1998-06-19 1999-10-12 Virginia Commonwealth University LZ-CD23 chimera for inhibition of IgE-mediated allergic disease
AU766190B2 (en) * 1998-10-16 2003-10-09 Biogen Idec Ma Inc. Interferon-beta fusion proteins and uses
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
WO2000032634A1 (en) * 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
JP2005522192A (ja) * 2001-07-19 2005-07-28 パーラン セラピューティクス， インコーポレイテッド マルチマータンパク質およびマルチマータンパク質を作製および使用する方法

Also Published As

Publication number Publication date
ES2245052T3 (es) 2005-12-16
AU756139B2 (en) 2003-01-02
DE69829995D1 (de) 2005-06-02
DK1039931T3 (da) 2005-08-08
EP1039931A4 (de) 2001-01-03
US20080299121A1 (en) 2008-12-04
CA2313028A1 (en) 1999-06-10
DE69829995T2 (de) 2006-02-23
WO1999027964A1 (en) 1999-06-10
AU1614699A (en) 1999-06-16
EP1039931B1 (de) 2005-04-27
EP1039931A1 (de) 2000-10-04

Similar Documents

Publication Publication Date Title
ATE230417T1 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
ATE330631T1 (de) Antikörperfragmente zur lokalen behandlung von augenerkrankungen
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
YU46097A (sh) Nova klasa estara i njihove farmaceutske smeše
DE69636760D1 (de) Rekombinanter anti-cd4 antikörper zur menschlichen behandlung
DE69533855D1 (de) UNTERBRECHUNG DER BINDUNG DER PROTEINE MDM2 UND p53 UND ENTSPRECHENDE THERAPEUTISCHE ANWENDUNG
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
BR9711805A (pt) Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
ATE290315T1 (de) Von humanem hitzeschockprotein 60 hergeleitete peptide zur behandlung von diabetis, entsprechende zusammensetzungen, verfahren und kits
ATE258057T1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
DE69829995D1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
ATE198990T1 (de) Konjugat zur behandlung von entzündlichen erkrankungen
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
FI963170A0 (fi) Menetelmä solujen poikkeavuudesta kärsivien yksilöiden tunnistamiseks i
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
ATE203680T1 (de) Konjugat zur behandlung von entzündungserkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1039931

Country of ref document: EP